FDA Drug Approvals and Changes: August Edition

Contributor Information

Author

Mary L Windle, PharmD
Editor-in-Chief, Medscape Drug Reference

References

1. Corey GR, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014 Jun 5;370(23):2180-90. PMID: 24897083.
2. Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. PMID: 24450857.
3. Gopal AK, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. PMID: 24450858.
4. Roden M, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. PMID: 24622369.
5. Ridderstrale M, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Jun 16. PMID: 24948511.
6. Koch A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. PMID: 25045258.
7. Ferguson GT, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014 Jun 16;9:629-45. PMID: 24966672.
8. Riedl MA, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):163-169. PMID: 24468257.
9. Korobelnik JF, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Jul 8. pii: S0161-6420(14)00426-6. PMID: 25012934.
10. Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. PMID: 24881631.
11. Lumizyme (alglucerase alfa) prescribing information. Genzyme Corp; Cambridge, MA. August 2014. Available at: http://www.lumizyme.com/~/media/LumizymeUS/Files/lumizyme_prescribing_information.pdf